Discontinuation syndromes with selective serotonin reuptake inhibitors : Are there clinically relevant differences?

• Published in: CNS drugs Vol. 12; no. 3; pp. 171 - 177
• Main Authors: OLVER, J. S, BURROWS, G. D, NORMAN, T. R
• Format: Journal Article
• Language: English
• Published: Hong Kong Adis International 01.09.1999; Auckland
• Subjects: Biological and medical sciences; Drug toxicity and drugs side effects treatment; Medical sciences; Miscellaneous (drug allergy, mutagens, teratogens...); Pharmacology. Drug treatments; Human; Mood disorder; Pharmacokinetic pharmacodynamic relationship; Serotonin; Pathogenesis; Toxicity; Controlled therapeutic trial; Review; Reuptake inhibitor; Chemotherapy; Treatment; Antidepressant agent; Clinical trial; Pharmacokinetics; Comparative study
• ISSN: 1172-7047; 1179-1934
• DOI: 10.2165/00023210-199912030-00001

Selective serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitors (SSRIs), like the tricyclic antidepressants and monoamine oxidase inhibitors, are associated with a well recognised syndrome following discontinuation or dose reduction. There appear to be differences in the incidence of discontinuation syndromes within the class of SSRIs. Published case reports and adverse drug reaction reports both suggest the highest incidence of the syndrome with paroxetine and the lowest incidence with fluoxetine, while other SSRIs are associated with an intermediate incidence. Open label comparison and placebo-controlled double- blind studies support this contention. There is little evidence to separate discontinuation syndromes with different SSRIs on the basis of clinical presentation. Although the pathogenesis of SSRI discontinuation syndromes is unknown, both pharmacodynamic and pharmacokinetic factors may explain differences in incidence with individual SSRIs. SSRI discontinuation syndromes are usually mild and transient, and prevention is the most effective management strategy.